Periodontitis+High CRP Raise Preeclampsia Risk

The presence of both factors in pregnant women more than doubled the risk of either factor by itself.

BY KATE JOHNSON
Montreal Bureau

TORONTO — A combination of mater-
nal periodontal disease and high levels of maternal C-reactive protein is associated with a significantly increased risk of preeclampsia, compared with either risk factor alone, according to a new analysis of the Oral Conditions and Pregnancy Study.

“There seems to be some type of syn-
ergy when both are combined,” said Dr. Michael S. Ruma, who presented the find-
ings at the annual meeting of the Society for Gynecologic Investigation.

A secondary analysis of 775 healthy pregnant women who had oral examina-
tions and C-reactive protein (CRP) levels measured at enrollment (less than 26 weeks’ gestation) found that preeclampsia was more common in those with high CRP levels alone (OR 2.6), and those with moderate to severe periodontal disease (PD) alone (OR 2.6)—but a combination of high CRP levels and moderate to severe PD increased the odds ratio to 7.0.

A total of 31 women (4%) developed preeclampsia in the cohort. The rate of preeclampsia was greater among women with a high CRP level (above the 75th per-
centile) than for women with a low CRP level (at or below the 75th percentile): 7% and 3%, respectively. The addition of mild PD to the elevated CRP level significant-
tly increased the risk of preeclampsia from an odds ratio of 2.6 to 6.0 and moderate to severe PD increased it further (OR 7.0).

“Maternal systemic inflammation may be in the causal pathway between peri-
odontal disease and the development of preeclampsia,” said Dr. Ruma of the Uni-
versity of North Carolina at Chapel Hill. However, he said, future research is re-
quired to further understand this phenom-
omenon. Both periodontitis and preeclampsia are multifactorial, but the implication is

that inflammation in the mother is leading to systemic disease,” he said in an interview.

A separate study presented at the meet-
ing suggests that such maternal inflam-
matation may also be transferred to the fe-
tus—particularly in the setting of maternal smoking. In a study of 277 women, Dr. John P. Newnham of the Women and In-
fants Research Foundation at King Ed-
ward Memorial Hospital in Perth, Western Australia, and his colleagues found that 12% of women with PD had babies who were small for gestational age (SGA), com-
pared with 2% of women who had healthy gums (“Gum Disease Again Tied to Pregnancy Outcomes,” O.GYN. NEWS, June 1, 2005, p. 28).

Further analysis of this study, which was presented at the meeting, found this effect is significantly increased (25%) in women who smoke. Additional-
ly, the researchers found that in smokers, both with and without PD, inflammatory markers (CRP and tumor necrosis fac-
tor-α) were significantly elevated in umbil-
cular cord blood, indicating an inflam-
atory response in the fetus.

“The thing I found absolutely fascinat-
ing was this marked inflammation in the fetus at birth as a result of the woman smoking in pregnancy—and PD added further to it,” Dr. Newnham said in an in-
terview. “Smoking not only increases the risk of PD, which everyone has known for a long time, but smoking increased the inflam-
atory markers in the cord blood and PD added to this.”

Although the absence of PD is associat-
ed with better obstetric outcomes, it is not known whether treating PD during preg-
nancy is beneficial or harmful, said Dr.
Newnham. “We are in equipoise. We know inflamed periodontal tissue can release cy-
tokines and prostanoids,” he said, lead-
ing some to hypothesize that the treat-
ment of PD could temporarily increase maternal systemic inflammation.

DRUGS, PREGNANCY, AND LACTATION

Gastrointestinal Agents: Part III

The final part of this series covers the use of infliximab, anticholin-
ergic/antispasmodics, gastrointestinal stimulants, and anorectal preparations in pregnant and lactating women.

► Infliximab (Remicade): Infliximab is a monoclonal antibody used to treat se-
vvere Crohn’s disease and autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, and psoriasis. It binds to and inhibits human tumor necrosis factor-α (TNF-α). Animal re-
production studies have not been con-
ducted with the agent because it does not react with animal TNF-α. Hu-
man pregnancy exposure consists of about 30 cases, which are limited to case reports and observational studies. The drug does not appear to represent a significant risk for devel-
 opmental toxicity. Still, if possible, the best course is to avoid its use in preg-
nancy. If pregnancy expo-
sure does occur, health care providers are encouraged to reg-
ister these patients in the Organization for Teratology Information Specialists (OTIS). Autoimmune Diseases in Pregn-
ancy study by calling the toll-free number, 877-311-8972.

► Anticholinergics/antispasmodics: These agents have been used for many years for peptic ulcer and functional GI disorders such as diarrhea, hyper-
motility, neurogenic colonic, irritable bowel syndrome, ulcerative colitis, bil-
ary tract spasm, and similar condi-
tions. The agents—available under nu-
merous trade names—include atropine, belladonna, dicyclomine, gly-
coprostyl, i-hysycine, meperdone-
late, metoclopramide, propantheline, and scopolamine.

Only atropine, scopolamine, and di-
cyclomine have sufficient data in preg-
nancy. There are no reports suggesting that these agents cause birth defects. However, an excessive dose of scopo-

lamine in labor has been associated with newborn toxicity. The other drugs are also probably low risk, but cannot be classified as such because of the very limited or complete lack of human pregnancy experience. How-
ever, anticholinergic combinations for-
mulated with phenobarbital or other sedatives should be avoided in preg-
nancy and lactation. Although the data are very limited, all anticholinergics, excep
t dibucaine, appear to be com-
patible with breast-feeding. Dicy-
clomine is concentrated in milk and has been associated with apnea in one nursing infant.

► GI stimulants: Dexpanthenol (Iopan) is given by intramuscular injec-
tion to prevent paralytic ileus after abdominal surgery. Although the drug has been promoted for constipation in pregnant women, there are no reports

of its use or studies in pregnant or lac-
tating animals or humans. Thus, the drug should not be given during preg-
nancy or breast-feeding.

In contrast, another GI stimulant, metoclopramide (Reglan, Maxolon), has substantial human pregnancy ex-
perience, primarily as an antiemetic. Al-
though it is considered compatible with pregnancy, its use during breast-feeding is controversial. It has been successfully used as a lactation stimulant at doses of 20-45 mg/day. The drug is excreted into milk, but the estimated dose ingested by a nursing infant from milk is much lower than the therapeu-
tic infant dose.

However, mild intesti-
 nal discomfort has been observed in two infants. Because of its dopamin-
ergic blocking action, the American Academy of Pediatrics classifies meto-
clopramide as a drug of potential concern during breast-feeding.

► Anorectal preparations: These in-
clude a large group of agents that are available in various topical formulations such as creams, ointments, foams, lotions, tissues, and supposi-
tories. With the exception of the hy-
drocortisone products, all are available over the counter, so you might not know that your patient is using them unless a careful history is taken. The OTC preparations are formulated with low concentrations of various drug mixtures, such as local anesthetics, vasconstrictors, antipruritics, emollients/protec-
tants, and antispasmodic agents.

Most GI agents are safe in pregnancy or lactation, but these prepa-
 rations are used for their local effects and clinically significant systemic levels are not expected. About 26% of the corticosteroid is ab-
sorbed from hydrocortisone supposi-
tories, but the maximum strength of these products is only 30 mg, so the amount reaching the circulation is clinically in-
significant. Therefore, at recommended doses, the use of anorectal prepara-
tions during pregnancy or breast-feed-
ing can be considered low risk.

Of the drugs covered in this series, misoprostol and tetracycline cause structural defects, castor oil can induce labor, and mesalamine-containing agents and diclofenac have caused toxicity in nursing infants. Most GI agents are safe in pregnancy and lacta-
tion, but many have insufficient data to judge their risk.

Mr. BRIGGS is a pharmacist clinical specialist, Women’s Pavilion, Miller Children’s Hospital, Long Beach, CA., and a clinical professor of pharmacy, University of California, San Francisco.